Published: October 15th 2024 | Updated: October 22nd 2024
Eye on Pharma: Aflibercept Legal Drama; PBM, Humira Biosimilars; Denosumab Regulatory Review
Published: October 15th 2024 | Updated: October 22nd 2024
Blue Shield of California Lowers Humira Biosimilar Costs, Challenges PBM Pricing
Published: June 8th 2021 | Updated: October 22nd 2024
Poll: Identify the Main Cause for Reverse Switching
Published: January 20th 2021 | Updated: October 22nd 2024
Poll: Which of the following is true about insulin products and the BPCIA?
Published: October 3rd 2024 | Updated: October 22nd 2024
Eye on Pharma: High-Strength Trastuzumab Biosimilar; Originator Coverage Removals; CHMP Aflibercept Opinion
Published: September 28th 2024 | Updated: October 22nd 2024
Patient-Reported Outcomes Similar Between Adalimumab-adbm, Reference Product in VOLTAIRE-RA Study